The variability in the impact of FAP+CAF content across different cancers and TME pathways underscores the complexity of the tumor microenvironment and the need for a tailored approach in the use of FAP as a therapeutic target and as a biomarker to inform patient enrichment strategies. This evidence concerns the gene FAP and cancer.